Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-Fat Diet Exacerbates Neuropathology in a Transgenic Mouse Model of Multiple System Atrophy.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Distinct neurostructural, cognitive, and neuropsychiatric associations of plasma p-tau217, and Aβ42/40 in Parkinson's disease and aging cohorts.

Frontiers in aging neuroscience·2026
Same author

Longitudinal Decline in Electrochemical Skin Conductance Reflects Disease Progression in Multiple System Atrophy.

European journal of neurology·2026
Same author

Plasma p-tau217 Versus p-tau181 in Parkinson's Disease: Differential Associations with Alzheimer's Disease-Related Neurostructural Changes and Cognitive Function.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Natural history and 12-month progression of multiple system atrophy in a Chinese cohort.

BMC neurology·2026
Same author

Sertraline Treatment Can Mimic Niemann-Pick Type C Biomarker Profile: A Diagnostic Pitfall.

Annals of clinical and translational neurology·2026
Same journal

New frontiers in acute reperfusion therapy for ischaemic stroke: from recanalisation to selection, delivery and safety.

Therapeutic advances in neurological disorders·2026
Same journal

Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensions.

Therapeutic advances in neurological disorders·2026
Same journal

Clinical, imaging, and immunotherapeutic features in MOGAD: a retrospective real-world cohort in Northern China.

Therapeutic advances in neurological disorders·2026
Same journal

Narcolepsy with co-occurring epilepsy: diagnostic pitfalls and management strategy.

Therapeutic advances in neurological disorders·2026
Same journal

Paradoxical myocardial infarction risk with dual antiplatelet therapy in East Asian ischaemic stroke: a nationwide real-world cohort study and pharmacogenomic risk prediction model.

Therapeutic advances in neurological disorders·2026
Same journal

Residual early neurological deterioration following dual antiplatelet in stroke: post hoc analysis of the ATAMIS trial.

Therapeutic advances in neurological disorders·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

Multiple system atrophy: current and future approaches to management.

Olivier Flabeau1, Wassilios G Meissner, François Tison

  • 1Department of Neurology, University Hospital of Bordeaux, Bordeaux, France.

Therapeutic Advances in Neurological Disorders
|December 24, 2010
PubMed
Summary
This summary is machine-generated.

Multiple system atrophy (MSA) is a rare neurodegenerative disease with no cure. Research explores alpha-synuclein

Keywords:
Parkinsonismmultiple system atrophyneurodegenerative diseasesneuroprotective agentstherapeutic

More Related Videos

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
04:41

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

Related Experiment Videos

Last Updated: Jun 5, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
04:41

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

Area of Science:

  • Neuroscience
  • Neurology

Background:

  • Multiple system atrophy (MSA) is a rare, fatal neurodegenerative disorder.
  • Characterized by Parkinsonism, ataxia, and autonomic failure.
  • Current treatments offer limited symptomatic relief, with no disease-modifying therapies available.

Purpose of the Study:

  • To review current symptomatic treatments for MSA.
  • To discuss recent findings on neuroprotective drug studies.
  • To outline future management strategies for MSA.

Main Methods:

  • Literature review of available symptomatic treatments.
  • Analysis of recent studies on neuroprotective agents.
  • Discussion of diagnostic criteria and clinical trial methodologies.

Main Results:

  • Symptomatic management of MSA remains challenging.
  • Alpha-synuclein aggregation is implicated in MSA pathogenesis.
  • Transgenic and toxic animal models are used to test potential drugs.

Conclusions:

  • Standardizing diagnostic criteria and assessment is crucial for multicenter clinical trials.
  • Further research into neuroprotective drugs targeting alpha-synuclein is warranted.
  • Developing effective treatments to slow or halt MSA progression is a key goal.